Top U.S. cholesterol-lowering drugs based on revenue 2013
Top HMG-CoA reductase inhibitors based on U.S. revenue in 2013 (in million U.S. dollars)
This statistic depicts the top ten HMG-CoA reductase inhibitors based on total U.S. revenue in 2013. In that year, Livalo was among the leading HMG-CoA reductase inhibitors generating a revenue of 124 million U.S. dollars in the United States. HMG-CoA reductase inhibitors or statins help lower cholesterol levels and is central in cholesterol production within the liver. It is used to prevent heart disease and decrease mortality within those with pre-existing cardiovascular disease.
Top HMG-CoA reductase inhibitors based on U.S. revenue in 2013 (in million U.S. dollars)
Source
More information
Statistics on "Pharmaceutical trends in Europe"
Discover Statista
Need help with using Statista for your research?
Tutorials and first steps
Further Content: Statistics, Studies, and Topic Pages
Statistics
- Top U.S. cholesterol-lowering drugs - market share by prescriptions 2013
- Top U.S. cholesterol-lowering drugs by revenue market share 2013
- Top U.S. cholesterol-lowering drugs based on prescriptions 2013
- Consumption of anti-cholesterol products in OECD member states 2015
- Top U.S. SNRIs based on prescriptions 2013
- Top U.S. market share of SNRIs based on precriptions 2013
- Top U.S. SNRIs based on revenue 2013
- Top U.S. market share of SNRIs based on revenue 2013
- Top U.S. proton pump inhibitors based on prescriptions 2013
- Price disparities for Zetia - U.S. and international 2017
- Italy: sales value of cardiovascular system drugs 2011-2017
- Argentina: cardiovascular system pharmaceuticals market revenue 2017-2018
- Lipid-modifying agents pharmaceutical consumption in Spain 2004-2014
- Drug production value of cardiovascular agents Japan 2016, by category
- U.S. cardiovascular company IPO financing volume 2006-2017
- U.S. adults aged 40+ using prescription cholesterol-lowering drugs by condition 2012
- Journal media spending of cardiovascular products U.S. 2016
- U.S. adults aged 40-64 using prescribed cholesterol-lowering drugs by insurance 2012
- U.S. branded prescription revenue forecast 2009-2015
- High-priced products on the U.S. pharmaceutical market 1995-2010
Statistics on "Pharmaceutical trends in Europe"
Related topics
About Statista
